BIOCRYST ANNOUNCES FDA APPROVAL OF ORLADEYO® (BEROTRALSTAT) ORAL PELLETS, FIRST AND ONLY ORAL PROPHYLACTIC TREATMENT FOR PATIENTS WITH HAE AGED 2 TO <12 YEARS

Reuters · 1d ago

Please log in to view news